Malignant Peritoneal Mesothelioma

  • Ning Ning


In 1908, Miller and Wynn firstly described a malignant mesothelioma (MPM), a type of aggressive and dismal malignancies that originates in the serosal layer of pleura, peritoneum, pericardium, and tunica vaginalistestis. MPM is mostly located in the pleural region and accounts for 30% of all mesotheliomas, with an estimated annual incidence of approximately 10,000 cases in China. Notably, the prevalence of MPM has been increased rapidly worldwide since 1970 and is not expected to reach the peak in another 1–2 decades. It has been reported that the lifetime probability of developing a peritoneal mesothelioma is 1/10,000 in women and 1–1.5/10,000 in men. In developed countries, MPM is the most common peritoneal malignancy. Because of high malignancy and frequent recurrence, either untreated or conventionally treated, the life expectancy of patients is restricted to be 4–12 months.


  1. Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008;14(8):1159–66.CrossRefPubMedCentralGoogle Scholar
  2. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007;9:32.PubMedPubMedCentralGoogle Scholar
  3. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7:147–54.CrossRefPubMedCentralGoogle Scholar
  4. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009a;99:109–13.CrossRefPubMedCentralGoogle Scholar
  5. Chua TC, Yan TD, Morris DL. Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg. 2009b;52(1):59–64.PubMedPubMedCentralGoogle Scholar
  6. Clin B, Morlais F, Dubois B, Guizard AV, Desoubeaux N, Marquignon MF, et al. Occupational asbestos exposure and digestive cancers – a cohort study. Aliment Pharmacol Ther. 2009;30(4):364–74.CrossRefPubMedCentralGoogle Scholar
  7. Davidson B. New diagnostic and molecular characteristics of malignant mesothelioma. Ultrastruct Pathol. 2008;32(6):227–40.CrossRefPubMedCentralGoogle Scholar
  8. de Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori. 2005;91(1):1–5.PubMedPubMedCentralGoogle Scholar
  9. Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98:268–72.CrossRefPubMedCentralGoogle Scholar
  10. Hassan R, Alexander R, Antman K, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006;17:1615–9.CrossRefPubMedCentralGoogle Scholar
  11. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2009;133:1317–31.PubMedPubMedCentralGoogle Scholar
  12. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings—a feasibility study. AJR Am J Roentgenol. 2009;193:461–70.CrossRefPubMedCentralGoogle Scholar
  13. Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18(2):e84–96.CrossRefPubMedCentralGoogle Scholar
  14. Mongero LB, Beck JR, Kroslowitz RM, et al. Treatment of primary peritoneal mesothelioma by hyperthermic intraperitoneal chemotherapy. Perfusion. 1999;14:141–5.CrossRefPubMedCentralGoogle Scholar
  15. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44.CrossRefPubMedCentralGoogle Scholar
  16. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181–8.CrossRefPubMedCentralGoogle Scholar
  17. Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol. 2008;191:814–25.CrossRefPubMedCentralGoogle Scholar
  18. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408.CrossRefPubMedCentralGoogle Scholar
  19. Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013;20:555–61.CrossRefPubMedCentralGoogle Scholar
  20. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res. 1996;82:235–53.CrossRefPubMedCentralGoogle Scholar
  21. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23(5):431–42.CrossRefGoogle Scholar
  22. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12(3):605–21. xiCrossRefPubMedCentralGoogle Scholar
  23. Suzuki Y. Diagnostic criteria for human diffuse malignant mesothelioma. Acta Pathol Jpn. 1992;42(11):767–86.PubMedPubMedCentralGoogle Scholar
  24. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(9):948–53.CrossRefPubMedCentralGoogle Scholar
  25. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827–34.CrossRefPubMedCentralGoogle Scholar
  26. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.CrossRefPubMedCentralGoogle Scholar
  27. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117(9):1855–63.CrossRefPubMedCentralGoogle Scholar
  28. Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35(9):980–5.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2018

Authors and Affiliations

  1. 1.Peking University International HospitalBeijingChina

Personalised recommendations